| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5962501 | ENDO PHARMS | Enantiomer of carbazole derivative as 5-HT1-like agonists |
Dec, 2013
(10 years ago) | |
| US5616603 | ENDO PHARMS | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
Apr, 2014
(10 years ago) | |
| US5637611 | ENDO PHARMS | Medicaments |
Jun, 2014
(9 years ago) | |
| US5827871 | ENDO PHARMS | Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof |
Oct, 2015
(8 years ago) | |
| US5464864 | ENDO PHARMS | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists |
Nov, 2015
(8 years ago) | |
Frova is owned by Endo Pharms.
Frova contains Frovatriptan Succinate.
Frova has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Frova are:
- US5962501
- US5616603
- US5637611
- US5827871
- US5464864
Frova was authorised for market use on 08 November, 2001.
Frova is available in tablet;oral dosage forms.
Frova can be used as acute treatment of migraine attacks with or without aura in adults.
The generics of Frova are possible to be released after 07 November, 2015.
Drugs and Companies using FROVATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 08 November, 2001
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: TABLET;ORAL
How can I launch a generic of FROVA before it's drug patent expiration?
More Information on Dosage
FROVA family patents
